Five pharmaceutical companies have reported million-dollar increases in their spending on lobbying the federal government during the first quarter of 2014. Pfizer Inc., Novartis, Johnson & Johnson Services, Bayer Corporation, and Merck & Company have each boosted their lobbying of the executive and legislative branches. Here are the top pharmaceutical spenders in the first quarter of 2014: Pharmaceutical Research & Manufacturers (PhRMA) $4,680,000 - up from $4,050,000 in 2013 Q4. Pfizer Inc. $3,190,000 - up from $2,090,000. Novartis $2,580,000 - up from $920,000. Amgen USA Inc. $2,560,000 - up from $2,330,000. Eli Lilly & Co. $2,086,000 - down from $2,430,000. Johnson & Johnson Services $2,110,000 - up from $860,000. Bayer - $2,040,000, up from $1,000,000. Merck & Co. $2,000,000 - up from $820,000 Glaxosmithkline $1,630,000 - up from $421,000. (Corrected) Sanofi US Services Inc. $1,570,000 - up from $790,000. (more…)
